-DOCSTART- -X- O
Ferroquine -X- _ B-Intervention
( -X- _ I-Intervention
FQ -X- _ I-Intervention
, -X- _ I-Intervention
SSR97193 -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
currently -X- _ O
the -X- _ O
most -X- _ O
advanced -X- _ O
organometallic -X- _ O
drug -X- _ O
candidate -X- _ O
and -X- _ O
about -X- _ O
to -X- _ O
complete -X- _ O
phase -X- _ O
II -X- _ O
clinical -X- _ O
trials -X- _ O
as -X- _ O
a -X- _ O
treatment -X- _ O
for -X- _ O
uncomplicated -X- _ B-Patient
malaria. -X- _ I-Patient
This -X- _ O
ferrocenecontaining -X- _ B-Intervention
compound -X- _ I-Intervention
is -X- _ O
active -X- _ B-Outcome
against -X- _ I-Outcome
both -X- _ I-Outcome
chloroquine-susceptible -X- _ I-Outcome
and -X- _ I-Outcome
chloroquine- -X- _ I-Outcome
resistant -X- _ I-Outcome
Plasmodium -X- _ I-Outcome
falciparum -X- _ I-Outcome
and -X- _ I-Outcome
P. -X- _ I-Outcome
vivax -X- _ I-Outcome
strains -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
isolates. -X- _ I-Outcome
This -X- _ O
article -X- _ O
focuses -X- _ O
on -X- _ O
the -X- _ O
discovery -X- _ O
of -X- _ O
FQ -X- _ O
, -X- _ O
its -X- _ O
antimalarial -X- _ O
activity -X- _ O
, -X- _ O
the -X- _ O
hypothesis -X- _ O
of -X- _ O
its -X- _ O
mode -X- _ O
of -X- _ O
action -X- _ O
, -X- _ O
the -X- _ O
current -X- _ O
absence -X- _ O
of -X- _ O
resistance -X- _ O
in -X- _ O
vitro -X- _ O
and -X- _ O
recent -X- _ O
clinical -X- _ O
trials -X- _ O
. -X- _ O

